Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study
Damiano Baroncini, Angelo Ghezzi, Roberto Bergamaschi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Antonio Bertolotto(Neuroscience Institute), Elio Scarpini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Isabella Righini, Giulia Mallucci, Maria Pia Amato(University of Florence), Pietro Iaffaldano(University of Bari Aldo Moro), Lorena Lorefice(University of Cagliari), Monica Margoni(Vita-Salute San Raffaele University), Gianfranco Costantino(Ospedali Riuniti di Foggia), Emanuele D’Amico(University of Catania), Silvia Miante(University of Padua), Marta Simone(University of Bari Aldo Moro), Paolo Gallo(University of Padua), Francesco Patti(University of Catania), Marco Capobianco(Ospedale San Luigi Gonzaga), Giuseppe Fenu(University of Cagliari), Fulvia Fanelli(Azienda Ospedaliera Sant'Andrea), Cinzia Scandellari(Ospedale Policlinico San Martino), Paolo Bellantonio(Vita-Salute San Raffaele University), Giancarlo Comi(University of Milan), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), N. Milani(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Lucia Moiola(Vita-Salute San Raffaele University)
Cited by 62
Related Papers
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
|Journal of Neuroinflammation|2016|896
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624